Clinical trial

FASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Progressing on Chemoimmunotherapy Induction

NCT05703997

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2023-01-01

PhasePHASE2

Study timeline

Study start (estimated)2023-01-01Date precision: month

Registry last updated2023-01-30

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Small Cell Lung Carcinomaunresolved

Interventions

Cyclic, 5-day calorie restrictionDIETARY_SUPPLEMENT

AtezolizumabDRUG · verified · RxNorm: atezolizumab

Sponsors & collaborators

Fondazione IRCCS Istituto Nazionale dei Tumori, Milanolead sponsor

IFOM ETS - The AIRC Institute of Molecular Oncologycollaborator

University of Milancollaborator

Mapped research locations

MilanItaly1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05703997 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.